A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants
NCT ID: NCT06715683
Last Updated: 2025-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
48 participants
INTERVENTIONAL
2024-12-12
2025-03-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants
NCT06577259
Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants
NCT03035734
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
NCT07226817
An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants
NCT03739788
A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants
NCT06568458
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1, Sequence 1
BMS-986278 Batched method, Dose A
Specified dose on specified days
BMS-986278 Batched method, Dose B
Specified dose on specified days
Part 1, Sequence 2
BMS-986278 Batched method, Dose A
Specified dose on specified days
BMS-986278 Batched method, Dose B
Specified dose on specified days
Part 2, Sequence 1
BMS-986278 Batched method, Dose A
Specified dose on specified days
BMS-986278 Continuous method
Specified dose on specified days
Part 2, Sequence 2
BMS-986278 Batched method, Dose A
Specified dose on specified days
BMS-986278 Continuous method
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986278 Batched method, Dose A
Specified dose on specified days
BMS-986278 Batched method, Dose B
Specified dose on specified days
BMS-986278 Continuous method
Specified dose on specified days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI) 18.0 to 32.0 kg/m2, inclusive.
* Body weight ≥ 50 kg for males and ≥ 45 kg for females.
Exclusion Criteria
* Current or recent (within 3 months of study intervention administration) gastrointestinal (GI) disease or other procedures (eg, bariatric procedures) that could affect drug absorption, distribution, metabolism, and excretion. Note: uncomplicated appendectomy and hernia repair are acceptable).
* Any major surgery within 4 weeks of study intervention administration on Day 1, including GI surgery (eg, cholecystectomy and any other GI surgery or perforation that could impact upon the absorption of study intervention \[uncomplicated appendectomy and hernia repair are acceptable\]).
* History of known risk of bleeding.
* Inability to tolerate oral medication.
* Individuals (only females) who are of childbearing potential.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anaheim Clinical Trials (ACT)
Anaheim, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM027-1035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.